Pre-post Evaluation of the Safety and Efficacy of Ibogaine-Magnesium Therapy in Veterans With Repeated Blast Exposure

This observational cohort study (n=30) evaluated the safety and efficacy of Ibogaine-Magnesium Therapy in veterans with sequelae of repeated blast exposure. Conducted by Stanford University, the study focuses on assessing the impact of this therapy on veterans who have experienced traumatic brain injury (TBI) and associated complications like PTSD, depression, and anxiety. Participants, male veterans aged 18-70 with a history of head trauma or blast exposure, were observed before and after receiving the treatment.

The study aims to provide a better understanding of the potential benefits and risks of Ibogaine-Magnesium Therapy, which remains under-researched despite its use among veterans seeking alternative treatments. The primary outcome measure is the change in the World Health Organization Disability Assessment Schedule 2.0 (WHODAS) scores from baseline to immediately post-treatment and at a one-month follow-up. The safety profile will be evaluated through the assessment of unexpected or serious adverse events. This study, which began in November 2021, is estimated to complete by February 2024. It’s significant as it addresses the urgent need for effective treatments for veterans suffering from the long-term effects of combat-related TBI.

Topic Traumatic Brain Injury
Compound Ibogaine
Country Mexico
Visit trial
Status Completed
Results Published Yes
Start date 15 November 2021
End date 01 February 2024
Chance of happening 100%
Phase Not Applicable
Design Open
Type Observational
Generation First
Participants 30
Sex Male
Age 18- 70
Therapy No

Trial Details

Traumatic brain injury (TBI) is a leading cause of disability worldwide and is particularly common among combat veterans. Deleterious sequelae can include functional impairments and comorbid psychiatric syndromes such as posttraumatic stress disorder (PTSD), depression, and anxiety. Special Operations Forces Veterans (SOV) may be at an elevated risk for these complications, leading some to seek treatment alternatives like the oneirogen ibogaine despite limited evidence of safety or efficacy. We will assess the safety profile of the compound by assessing unexpected or serious adverse events. The primary outcome will be change in the World Health Organization Disability Assessment Schedule 2.0 (WHODAS) from baseline to post-treatment, with change from baseline to the one-month follow-up a secondary outcome.

NCT Number NCT04313712

Sponsors & Collaborators

Stanford University
Researchers at Stanford are exploring the potential of ketamine, MDMA and psilocybin by connecting neuroscience, psychiatry and anesthesiology.

Papers

Magnesium–ibogaine therapy in veterans with traumatic brain injuries
This observational study (n=30) evaluates ibogaine (up to 980mg/70kg) in combination with magnesium (1-2 hours before and 12 hours later) in male Special Operations Forces veterans with predominantly mild traumatic brain injury (mTBI). The study assessed changes in disability, PTSD, depression, and anxiety immediately and one month after treatment using various scales. Results show significant improvements in functioning and psychological symptoms with no serious adverse events.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.